Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Recruiting now Phase 2 NCT06297226
Run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · for 18 and older · All sexes
What this study is about
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Who can join (things the study team will check)
✅ You may be able to join if…
- Documented diagnosis of multiple myeloma (MM) as per International Myeloma Working Group (IMWG) criteria.
- Received at least 4 classes of MM treatment [including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, anti-BCMA therapy, and at least 3 prior lines of therapy (LOT).
- Documented disease progression during or after their last anti-myeloma regimen as per IMWG 2016 criteria.
- Participants must have measurable disease during screening.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
🚫 You may not be able to join if…
- Active or history of central nervous system involvement with MM.
- Active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis. Participants with severe infection, severe sepsis or bacteremia in the last 28 days prior to leukapheresis are excluded.
- Received any prior therapy directed at G protein-coupled receptor class C, group 5, member D (GPRC5D) or has received other prior treatment for MM without the required washout prior to leukapheresis.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Where this trial is running
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- UCLA Hematology/Oncology - Westwood (Building 200 Suite 214), Los Angeles, California, United States
- UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco, California, United States
- Colorado Blood Cancer Institute, Denver, Colorado, United States
- Mayo Clinic in Florida, Jacksonville, Florida, United States
- Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
- Northside Hospital, Atlanta, Georgia, United States
- Northwestern Memorial Hospital, Chicago, Illinois, United States
+ 40 more sites.
Who to contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06297226.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.